Daily statin medication could improve cardiovascular outcomes in people with HIV

A National Institutes of Health clinical trial was stopped early because a daily statin medication was found to reduce the increased risk of cardiovascular disease among people living with HIV in the first large-scale clinical study to test a primary cardiovascular prevention strategy in this population.

Related Keywords

Massachusetts ,United States ,Harvard University ,America ,Pamela Douglas ,Michaelt Lu ,Steven Grinspoon ,Emily Henderson ,Heather Ribaudo ,Garyh Gibbons ,Hugh Auchincloss ,Department Of Biostatistics At Harvard University ,Neat Id Foundation ,Data Coordinating Center ,Clinical Trials Group ,National Heart ,A National Institutes Of Health ,Kowa Pharmaceuticals America Inc ,Gilead Sciences Inc ,Clinical Coordinating Center ,Duke University Department Of Medicine ,Ursula Geller Professor Of Research ,Blood Institute ,Hospital Cardiovascular Imaging Research Center ,National Institute Of Allergy ,National Institutes ,Randomized Trial ,Prevent Vascular Events ,Data Safety ,Monitoring Board ,North America ,South America ,National Institute ,Infectious Diseases ,Trials Group ,Massachusetts General Hospital ,Clinical Coordinating ,Ursula Geller Professor ,Cardiovascular Diseases ,Duke University Department ,Data Coordinating ,Kowa Pharmaceuticals America ,Gilead Sciences ,Cardiovascular Disease ,Shiv ,Statin ,Kids ,Antiretroviral ,Flood ,Calcium ,D4 ,Fell ,Cholesterol ,Clinical Trial ,Efficacy ,Heart ,Hospital ,Medical Research ,Medicine ,Metabolism ,Pitavastatin ,Placebo ,Research ,Ascular ,